Results 151 to 160 of about 276,919 (299)

Intima‐Media Thickness Progression Rate and Primary Unassisted Patency Failure in Arteriovenous Fistulas: A Prospective Cohort Study

Hemodialysis International, EarlyView.
ABSTRACT Background Failure of autogenous arteriovenous fistulas (AV fistulas) due to venous neointimal hyperplasia is a major clinical challenge. Whether the rate of progression in venous intima‐media thickness predicts primary unassisted patency failure remains unknown.
Gen Li, Zhengjiang Cao
wiley   +1 more source

Walsh & Hoyt: Thrombosis of the Cavernous Sinus

, 2005
Clinical presentations of cavernous sinus thrombosis are influenced by the mechanism of thrombosis, specifically whether the condition is infectious or ...
Valerie A. Purvin, MD
core  

Utility of the SWAM (Separator With Aspirator for Mechanical Thrombectomy) Device in Managing Hemodialysis Access Thrombosis

Hemodialysis International, EarlyView.
ABSTRACT Background Hemodialysis access thrombosis is the primary cause of access failure. Thrombus removal is an effective strategy to restore access function. Although both open surgical and endovascular procedures enable thrombus clearance, endovascular thrombus reduction therapy is widely adopted in clinical practice for this condition due to its ...
Lin Li, Zhongwang Zhang, Hongjie Wang, Mingdi Zhu, Kun Wang, Zheng Liu   +5 more
wiley   +1 more source

High intracranial pressure, brain herniation and death in cerebral venous thrombosis [PDF]

, 2006
Petzold, A, Smith, M
core  

The Incidence of Sinus Thrombosis in Presumed Idiopathic Intracranial Hypertension

, 2003
Idiopathic intracranial hypertension (IIH) occurs most commonly in obese women of childbearing age. Neuroimaging is required to rule out sinus thrombosis or brain tumors.
Catherine I. Barry, MD; Robert A. Egan, MD
core  

Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Allison C. Hyland, Samuel J. Belfer, Christine K. Fox, Samantha L. Irwin, Rachel Vassar, Ann Oh, Sruthi Ilangovan, Amy A. Gelfand   +7 more
wiley   +1 more source

Neurological Manifestations of Dural Sinus Thrombosis

, 2012
This paper had been presented for promotion at the University of Khartoum. To get the full text please contact the other at Abbashar59@yahoo,comBackground:Dural sinus thrombosis is a clinical syndrome that has a diversity of signs and symptoms that can ...
Hussein, Abbashar
core  

Cisterna Chyli Dilation Is a Risk Factor for Liver Nodules and Hepatocellular Carcinoma in Fontan‐Associated Liver Disease: Pathophysiological Role of Lymphatic Dysfunction

Hepatology Research, EarlyView.
ABSTRACT Aim In Fontan‐associated liver disease (FALD), chronic congestion often confounds conventional fibrosis markers, complicating surveillance for hepatocellular carcinoma (HCC). Although lymphatic dysfunction is fundamental to Fontan physiology, its contribution to hepatocarcinogenesis remains unclear.
Koji Imoto, Masatake Tanaka, Takeshi Goya, Yuuki Azuma, Tomonobu Hioki, Yusuke Morita, Keisuke Sakaguchi, Nobuhiro Fujita, Takamori Kakino, Ayako Ishikita, Kenichiro Yamamura, Ichiro Sakamoto, Kousei Ishigami, Kohtaro Abe, Yoshihiro Ogawa   +14 more
wiley   +1 more source

Clinical Outcomes After Catheter Ablation in Patients With Structural Heart Disease and Ventricular Fibrillation

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Introduction In patients with ischemic cardiomyopathy (ICM), recurrent VF may be treated with catheter ablation by targeting triggering premature ventricular complexes (PVCs) and/or ventricular scar homogenization. Data on optimal ablation strategies in patients with non‐ischemic cardiomyopathy (NICM) remain limited.
Kenji Hashimoto, Samual Turnbull, Saurabh Kumar   +2 more
wiley   +1 more source

A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In moderate‐to‐severe plaque psoriasis, socrodeucitinib (6 mg/12 mg) significantly outperformed placebo at week 12: PASI 75 response rates 28.6%/72.1% vs. 7.5%. Meanwhile, socrodeucitinib illustrated a favourable safety and tolerability profile, warranting further study.
Ling Han, Songmei Geng, Yangfeng Ding, Shifa Zhang, Xiaohua Wang, Fengming Hu, Jianguo Li, Chao Ci, Yayu Hu, Rixin Chen, Jianping Zhang, Xiaoyong Zhou, Aijun Chen, Chunlei Zhang, Tiechi Lei, Yanyan Feng, Yu Wang, Zudong Meng, Yan Zhou, Mingkai Ji, Wei Liu, Yunting Wu, Qianying Chen, Siyi Wang, Jinhua Xu   +24 more
wiley   +1 more source